DexCom stock falls after Hunterbrook issues short report on G7 device

DexCom (DXCM) shares declined 3% following a short report by Hunterbrook Media, which alleges critical safety issues with the company's G7 continuous glucose monitoring device. The report claims an unauthorized design change to a key component, despite internal studies showing its inferiority, has led to inaccurate readings, patient harm, and widespread complaints, prompting some doctors to cease G7 prescriptions. Hunterbrook also raised concerns about DexCom's aggressive accounting practices and an executive exodus, including the CEO's unexpected departure, while disclosing a short position in DXCM shares, indicating significant operational, regulatory, and reputational risks.

Analysis

DexCom (DXCM) shares experienced a 3% decline following the publication of a highly negative short report from Hunterbrook Media, which outlined severe allegations against the company's G7 continuous glucose monitoring device. The core of the report centers on product safety and regulatory non-compliance, claiming DexCom implemented an unauthorized design change to a key G7 sensor component. Hunterbrook asserts that internal studies showed this new component to be inferior on "every accuracy metric" and that the company proceeded with sales despite FDA inspection documents showing a failure to prove equivalence with the original. These product-related claims are substantiated with anecdotal evidence of patient hospitalizations and a death, along with the growth of a 58,000-member patient complaint group on Facebook. Beyond product issues, the report raises significant financial and governance red flags, pointing to "aggressive accounting tactics" evidenced by Days Sales Outstanding (DSO) ballooning past 100 days, well outside the normal 30-90 day range. This is compounded by concerns of an "executive exodus," highlighted by the unexpected early departure of CEO Kevin Sayer. Hunterbrook Capital's disclosure of a short position in DXCM, hedged with derivatives, underscores the multi-faceted risk profile presented, spanning operational, regulatory, financial, and leadership challenges.

Key Decisions for Investors

• Investors should closely monitor for an official response from DexCom addressing the specific allegations regarding the G7's unauthorized design change and sensor accuracy, as the credibility of its rebuttal will be critical for sentiment.
• The allegations of patient harm and FDA non-compliance create significant tail risk; therefore, it is crucial to watch for any regulatory actions, official investigations, or class-action lawsuits which would materially escalate legal and financial liabilities.
• The claim of Days Sales Outstanding exceeding 100 days warrants scrutiny of the company's upcoming financial statements, particularly accounts receivable and cash flow, to validate or disprove concerns about aggressive revenue recognition.
• Given the combined product safety, regulatory, financial, and governance risks, current holders should re-evaluate their exposure, while prospective investors should exercise extreme caution until the validity of the short-seller's claims is clarified.